Literature DB >> 6831367

Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease.

W M Christopherson, P J Connelly, R C Alberhasky.   

Abstract

A review of the pathologic material from patients in our population based uterine cancer registry in Louisville, Kentucky identified three subtypes of endometrial carcinoma with a favorable prognosis: adenoacanthoma, adenocarcinoma with no specific features, and secretory carcinoma. Three subtypes with a much less favorable prognosis were papillary carcinoma, mixed adenosquamous carcinoma, and clear cell carcinoma. The other important determinants of treatment results were: stage of disease, age, race, nuclear grade, and depth of myometrial invasion. This study evaluated these prognostic determinants for the favorable subtypes with Stage 1 disease that were fully treated. There were 595 patient eligible for five-year and 380 for ten-year vital status evaluation. Only three patients were lost to follow-up at five years and four at ten years. The five-year survival was 88.1% and the ten-year 74.5%. At five years 4.4% were dead of disease and at ten years 6.3%. There were 115 women younger than age 50. Their five-year survival was 98.3% and at ten years 94.6%. None was dead of disease at five years and only one at ten years. Black women had a significantly lower survival than did white women, but no black woman younger than age 50 died of disease. Nuclear grade was the most important histologic determinant of survival, followed by depth of myometrial invasion. Recommendations for treatment planning were formulated based on these prognosticators.

Entities:  

Mesh:

Year:  1983        PMID: 6831367     DOI: 10.1002/1097-0142(19830501)51:9<1705::aid-cncr2820510924>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma.

Authors:  H Hareyama; N Sakuragi; S Makinoda; S Fujimoto
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.

Authors:  A M Gassel; J Backe; S Krebs; S Schön; H Caffier; H K Müller-Hermelink
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

3.  MicroRNA signatures differentiate uterine cancer tumor subtypes.

Authors:  Elena S Ratner; David Tuck; Christine Richter; Sunitha Nallur; Rajeshvari M Patel; Vince Schultz; Pei Hui; Peter E Schwartz; Thomas J Rutherford; Joanne B Weidhaas
Journal:  Gynecol Oncol       Date:  2010-06-09       Impact factor: 5.482

Review 4.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

Review 5.  Sex steroid receptors in endometrial cancer.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1988 Jul-Aug

6.  Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer.

Authors:  A Lösch; P Kohlberger; G Gitsch; A Kaider; G Breitenecker; C Kainz
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

7.  Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.

Authors:  O Falcón; R Chirino; L León; A López-Bonilla; S Torres; L Fernández; J A García-Hernández; P F Valerón; J C Díaz-Chico
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  Proliferative cell index in endometrial adenocarcinoma of different nuclear grades.

Authors:  M Mushika; K Shibata; T Miwa; Y Suzuoki; T Kaneda
Journal:  Jpn J Cancer Res       Date:  1989-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.